Usanarat Anurathapan, Suradej Hongeng, Samart Pakakasama, Duantida Songdej, Nongnuch Sirachainan, Pongpak Pongphitcha, Ampaiwan Chuansumrit, Pimlak Charoenkwan, Arunee Jetsrisuparb, Kleebsabai Sanpakit, Piya Rujkijyanont, Arunotai Meekaewkunchorn, Yujinda Lektrakul, Pornchanok Iamsirirak, Pacharapan Surapolchai, Somtawin Sirireung, Rosarin Sruamsiri, Pustika Amalia Wahidiyat, Borje S Andersson
Patients with severe thalassemia commonly have a survival that is significantly shorter than that of the general population. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the only established treatment that is potentially curative, but it is limited by the availability of donors and the medical condition of the patient. To expand the donor pool to include haploidentical related donors, we introduced a program consisting of a pharmacologic pretransplant immune suppression phase (PTIS) and 2 courses of dexamethasone and fludarabine, followed by pretransplant conditioning with fludarabine-i...
June 2020: Biology of Blood and Marrow Transplantation